Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy.
Tazawa R, Inoue Y, Arai T, Takada T, Kasahara Y, Hojo M, Ohkouchi S, Tsuchihashi Y, Yokoba M, Eda R, Nakayama H, Ishii H, Nei T, Morimoto K, Nasuhara Y, Ebina M, Akira M, Ichiwata T, Tatsumi K, Yamaguchi E, Nakata K.
Tazawa R, et al. Among authors: nakayama h.
Chest. 2014 Apr;145(4):729-737. doi: 10.1378/chest.13-0603.
Chest. 2014.
PMID: 24158247
Clinical Trial.